- Tibolone, a hormone therapy widely available in Europe and Australia, ameliorates depression in women undergoing the menopausal transition, according to a double-blind randomized controlled trial.
Why this matters
- Adjunctive tibolone, with more research, may become a treatment option for perimenopausal women whose depression is notoriously hard to treat.
- Double-blind study enrolled 44 perimenopausal/early postmenopausal women with depression (first-onset, relapse, or persistent depressive symptoms).
- Participants were randomly assigned to adjunctive tibolone (2.5 mg/day; n=22) or placebo (n=22) group.
- Funding: National Health and Medical Research Council.
- The mean level of Montgomery Asberg Depression Rating Scale (MADRS) scores dropped about 1 point every 2 weeks (unconditional linear model; slope, −1.04).
- The slope negative regression coefficient showed that treatment with tibolone significantly predicted the linear slope (conditional latent growth model; P=.001).
- The MADRS scores in the tibolone group significantly dropped by 1.65 compared with placebo group.
- The 2 groups did not significantly differ in terms of side effects (range, P=.12 to P=.99).
- Effects of tibolone were only monitored over the course of 12 weeks.
Coauthored with Chitra Ravi, MPharm